Nicotinamide phosphoribosyltransferase in malignancy: a review.
Nicotinamide phosphoribosyltransferase in malignancy: a review.
复制标题
DOI：
10.1177/1947601913507576
复制
发表时间：
2013-11-01
期刊：
影响因子：
--
通讯作者：
Coppola, Domenico
中科院分区：
文献类型：
--
作者：
Shackelford, Rodney E;Mayhall, Kim;Coppola, Domenico
烟酰胺磷酸核糖转移酶（Nampt）催化烟酰胺腺嘌呤二核苷酸（NAD）合成的限速步骤。细胞内和细胞外Nampt（iNampt和eNampt）水平在几种人类恶性肿瘤中均升高，一些研究表明，在更具侵袭性/侵袭性的肿瘤和肿瘤转移中，iNampt升高。已经鉴定了几种不同的分子靶点，其在iNampt过表达后促进癌发生，包括SirT 1、CtBP和PARP-1。此外，eNampt在几种人类癌症中升高，并且通常与更高的肿瘤分期和更严重的肿瘤相关。在这里，我们回顾了Nampt在恶性肿瘤中的作用，一些已知的机制，它促进癌变，并讨论了采用Nampt抑制剂在癌症治疗的可能性。
Nicotinamide phosphoribosyltransferase (Nampt) catalyzes the rate-limiting step of nicotinamide adenine dinucleotide (NAD) synthesis. Both intracellular and extracellular Nampt (iNampt and eNampt) levels are increased in several human malignancies and some studies demonstrate increased iNampt in more aggressive/invasive tumors and in tumor metastases. Several different molecular targets have been identified that promote carcinogenesis following iNampt overexpression, including SirT1, CtBP, and PARP-1. Additionally, eNampt is elevated in several human cancers and is often associated with a higher tumor stage and worse prognoses. Here we review the roles of Nampt in malignancy, some of the known mechanisms by which it promotes carcinogenesis, and discuss the possibility of employing Nampt inhibitors in cancer treatment.